Types of Cancer We Treat

Melanoma

As one of the first skin cancer treatment programs in New York City, we have long been at the forefront of melanoma research and care. We created the ABCDE screening system—now a standard diagnostic tool—to help identify melanoma at an early stage, when treatment is most effective.

Our dermatologists, dermatopathologists, oncologic surgeons, reconstructive plastic surgeons, medical oncologists, radiation oncologists, and pathologists combine their expertise to customize a treatment plan for you.

Our melanoma surgeons specialize in removing the cancer while preserving appearance and function, and our medical oncologists provide the latest targeted treatments, including genetically engineered injectable therapies.

Find a Doctor & Schedule
Diagnosis
Surgery
Targeted Drugs & Immunotherapy
Radiation Therapy

Related News

Perlmutter Cancer Center Expands Clinical Trials Portfolio
Read Story
Algorithm Predicts Patient Response to Skin Cancer Treatment
Read Story
NYU Langone Melanoma Surgeon Advances Treatments
Read Story
Melanoma Skin Cancer Is Killing Fewest Americans in Decades
Read Story
Melanoma Program Co-Director Searches for New Treatments
Read Story
Circular RNA Limits Skin Cancer Spread
Read Story
NYU Langone Receives Grant for Melanoma Research
Read Story
Blood Test to Measure Effectiveness of Skin Cancer Treatment
Read Story
Treatment Options for Later-Stage Melanoma
Read Story
Investigators Develop Novel Blood Tests for Tumor DNA
Read Story
How a Mentor–Mentee Team Found a New Understanding of Cancer
Read Story
Cancer Experts Share Updates in Immunology Advances
Read Story

Clinical Trials and Research Studies

Phase 5

Phase I/II study of dabrafenib trametinib and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only).

Learn More

Phase 2

A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST) KEAP1/NRF2 and LKB1 Aberrant Tumors

Learn More

Phase 2

A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma and Other Rare Skin Tumors

Learn More

Phase 2

A Randomized Controlled Open-Label Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Learn More
View All Related Clinical Trials (20)